Talking About Tumors with Ryann and Ryan - A medical oncology podcast

02_03 Adjuvant endocrine therapy for early breast cancer

October 29, 2022 Talking About Tumors Season 2 Episode 3
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
02_03 Adjuvant endocrine therapy for early breast cancer
Show Notes

1.       Tamoxifen, its development, mechanism and benefits

2.       Aromatase inhibitors and their benefit in post-menopausal state

3.       Nuances on extended endocrine therapy beyond 5 years

4.       SOFT/TEXT, a broad overview of a complex publication

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references on this topic:


1.           Pagani O et al.. NEJM. 2014;371(2):107-118. doi:10.1056/NEJMOA1404037

2.           Francis PA et al. NEJM. 2018;379(2):122-137. doi:10.1056/NEJMOA1803164/

3.           Gnant M et al.  NEJM. 2021;385(5):395-405. doi:10.1056/NEJMOA2104162/

4.           Cuzick J et al. Lancet Oncol. 2010;11(12):1135-1141. doi:10.1016/S1470-2045(10)70257-6

5.           Regan MM  et al. Lancet Oncol. 2011;12(12):1101-1108. doi:10.1016/S1470-2045(11)70270-4

6.           Davies C et al.. The Lancet. 2013;381(9869):805-816. doi:10.1016/S0140-6736(12)61963-1

7.           Goss PE  et al.  NEJM. 2016;375(3):209-219. doi:10.1056/NEJMOA1604700/

8.           Goss PE et al. J Natl Cancer Inst. 2005;97(17):1262-1271. doi:10.1093/JNCI/DJI250

9.           Abe O  et al.   The Lancet. 2011;378(9793):771-784. doi:10.1016/S0140-6736(11)60993-8

10.        Jordan VC. A  Breast Cancer Research. 2003;5(6):294. doi:10.1186/BCR656

 

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology